Eugene Braunwald.

Benjamin M. Scirica, M.D common info ., M.P.H., Deepak L. Bhatt, M.D., M.P.H., Eugene Braunwald, M.D., P. Gabriel Steg, M.D., Jaime Davidson, M.D., Boaz Hirshberg, M.D., Peter Ohman, M.D., Robert Frederich, M.D., Ph.D., Stephen D. Wiviott, M.D., Elaine B. Hoffman, Ph.D., Matthew A. Cavender, M.D., M.P.H., Jacob A. Udell, M.D., M.P.H., Nihar R. Desai, M.D., M.P.H., Ofri Mosenzon, M.D., Darren K. McGuire, M.D., Kausik K. Ray, M.D., Lawrence A. Leiter, M.D., and Itamar Raz, M.D. For the SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and Cardiovascular Outcomes in Individuals with Type 2 Diabetes Mellitus Type 2 diabetes mellitus doubles the risk of major cardiovascular complications in sufferers with and in individuals without established cardiovascular disease,1-3 such that nearly all sufferers with diabetes die of cardiovascular diseases.4 Although improved glycemic control has been shown to lessen microvascular diabetic complications repeatedly,5 uncertainty remains regarding whether any particular glucose-lowering technique, or specific therapeutic agent, is safe and sound from a cardiovascular standpoint or may reduced cardiovascular risk actually.